Association between urate-lowering therapies and cognitive decline in community-dwelling older adults

Long-term use of urate-lowering therapies (ULT) may reduce inflammaging and thus prevent cognitive decline during aging. This article examined the association between long-term use of ULT and cognitive decline among community-dwelling older adults with spontaneous memory complaints. We performed a s...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-09, Vol.12 (1), p.15299-15299, Article 15299
Main Authors: Molet-Benhamou, Luc, Giudici, Kelly Virecoulon, de Souto Barreto, Philipe, Cantet, Christelle, Rolland, Yves
Format: Article
Language:English
Subjects:
692/4023
692/499
692/617
Aged
Aging
Allopurinol
Alzheimer Disease / prevention & control
Body mass index
Cognition
Cognitive ability
Cognitive Dysfunction / diagnosis
Dementia disorders
Diabetes mellitus
Humanities and Social Sciences
Humans
Hypertension
Independent Living
Life Sciences
multidisciplinary
Older people
Polyunsaturated fatty acids
Santé publique et épidémiologie
Science
Science (multidisciplinary)
Uric acid
Uric Acid / pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long-term use of urate-lowering therapies (ULT) may reduce inflammaging and thus prevent cognitive decline during aging. This article examined the association between long-term use of ULT and cognitive decline among community-dwelling older adults with spontaneous memory complaints. We performed a secondary observational analysis using data of 1673 participants ≥ 70 years old from the Multidomain Alzheimer Preventive Trial (MAPT Study), a randomized controlled trial assessing the effect of a multidomain intervention, the administration of polyunsaturated fatty acids (PUFA), both, or placebo on cognitive decline. We compared cognitive decline during the 5-year follow-up between three groups according to ULT (i.e. allopurinol and febuxostat) use: participants treated with ULT during at least 75% of the study period (PT ≥ 75; n = 51), less than 75% (PT 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-17808-6